Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma
暂无分享,去创建一个
Isabella Fermo | Clara Camaschella | I. Fermo | C. Camaschella | M. Ponzoni | M. Chesi | Alessandro Campanella | Maurilio Ponzoni | Marta Chesi | A. Campanella | Jessica Bordini | Maria Teresa Sabrina Bertilaccio | P. Leif Bergsagel | P. Bergsagel | M. T. Bertilaccio | J. Bordini
[1] S. Rivella. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. , 2012, Blood reviews.
[2] A. Trumpp,et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. , 2012, Blood.
[3] U. Testa,et al. Apoptotic mechanisms in the control of erythropoiesis , 2004, Leukemia.
[4] L. De Franceschi,et al. Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis. , 2013, Blood.
[5] Tomas Ganz,et al. Hepcidin and iron regulation, 10 years later. , 2011, Blood.
[6] Terry M Therneau,et al. Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.
[7] M. Oukka,et al. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[8] G. Weiss. Iron metabolism in the anemia of chronic disease. , 2009, Biochimica et biophysica acta.
[9] Angela C. Colmone,et al. Leukemic Cells Create Bone Marrow Niches That Disrupt the Behavior of Normal Hematopoietic Progenitor Cells , 2008, Science.
[10] Elizabeta Nemeth,et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. , 2010, Blood.
[11] M. Lidonnici,et al. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. , 2012, Blood.
[12] G. Tonon,et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib , 2013, Haematologica.
[13] H. Niederegger,et al. Autocrine formation of hepcidin induces iron retention in human monocytes. , 2008, Blood.
[14] Donald Limbrick,et al. Mouse Models of Anemia of Cancer , 2014, PloS one.
[15] P. L. Bergsagel,et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. , 2012, Blood.
[16] T. Ganz,et al. Involvement of Hepcidin in the Anemia of Multiple Myeloma , 2008, Clinical Cancer Research.
[17] E. Fung,et al. Manipulation of the hepcidin pathway for therapeutic purposes , 2013, Haematologica.
[18] P. L. Bergsagel,et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. , 2008, Cancer cell.
[19] T. Ganz,et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: Study of correlations with myeloma treatment, disease variables, and anemia response , 2009, American journal of hematology.
[20] F. Dammacco,et al. Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. , 2001, Blood.
[21] F. Dammacco,et al. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. , 2002, Blood.
[22] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[23] Kou-Juey Wu,et al. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. , 1999, Science.
[24] S. Modoni,et al. Clinical results of recombinant erythropoietin in transfusion‐dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis , 1997, European journal of haematology.
[25] D. Cella,et al. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. , 1997, Seminars in hematology.
[26] T. Hagve,et al. [Anemia of chronic disease]. , 2017, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.